AP NEWS

Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025 - ResearchAndMarkets.com

September 18, 2018

DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025” report has been added to ResearchAndMarkets.com’s offering.

The “Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025” report provides an extensive study on the marketed, clinical and preclinical products / product candidates for management of chronic pain. The report also features a detailed overview of the devices that are used for the treatment / management of pain associated with chronic clinical conditions.

Owing to the rapid onset of their medicinal effect, which offers immediate relief with high efficacy, opioids are still considered to be one of the most widely used pharmacological interventions for the management of moderate to severe forms of pain. However, these drugs are known to induce a euphoric state upon intake, often causing patients to abuse them; increased recreational use of opioids has also been shown to lead to drug addiction.

The over-prescription of such medicinal products, which promotes their misuse, is considered as one of the root causes of the opioid crisis. In a recent article, published in 2017, 11.5 million individuals were reported to have been caught misusing prescription opioids, while over 42,000 died from opioid overdose, in the US alone. Moreover, opioid abuse was estimated to have been responsible for over USD 500 billion worth of economic deficit (in the US) due to loss of productivity and healthcare costs.

The opioid crisis has prompted drug manufacturers to develop non-addictive, non-narcotic-based therapeutics / analgesics for the management of pain. Unlike opioids, non-opioid drugs do not affect receptors present in the brain and, thus, are not addictive. These drugs work directly on injured / diseased body tissues and generally block the production of prostaglandins by inhibiting the cyclooxygenase (COX) enzyme at the site of injury / infection, thereby, decreasing the generation of pain mediators within the peripheral nervous system.

Additionally, there are various pain management devices that have been reported to significantly reduce or eliminate the need for pharmacological interventions. Such devices are increasingly being used to treat a variety of clinical conditions that are characterized by chronic pain and offer the convenience of being used in the homecare setting as well. However, it is imperative for patients to consult qualified healthcare professionals, who have the required understanding of such therapeutic options, prior to using such devices

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term, for the period 2018-2025. The report includes a detailed market segmentation on the basisof indication (chronic back pain, lumbar radiculopathy, migraine, osteoarthritis and neuropathic pain), type of molecule (small molecule and biologic), mechanism of action (CGRP inhibitors, COX/ NGF inhibitors, TRPV1 receptor antagonists, channel blockers and others) and geography (North America, Europe, Asia Pacific and rest of the World). In addition, the report features an opportunity analysis for the chronic pain management devices market. The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Ryan Jeffcoat (Director of Clinical Affairs & New Markets, AVACEN Medical), Lisa Robin (Chief Advocacy Officer, Federation of State Medical Boards), Nelson Hendler (Chief Executive Officer, Mensana Clinic Diagnostics) and Mark Wiederhold (Chief Executive Officer, Virtual Reality Medical Center). All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Chronic Pain Management: Unmet Need Analysis

5. Pipeline Review: Marketed And Development Drugs

6. Lifecycle Management Strategies For Marketed Products

7. Drug Profiles: Late Stage Molecules

8. Chronic Pain Management Devices: Market Landscape

9. Device Competitiveness Analysis And Profiles

10. Partnerships And Collaborations

11. Funding And Investment Analysis

12. Market Forecast And Opportunity Analysis

13. Conclusion

14. Executive Insights

For more information about this report visit https://www.researchandmarkets.com/research/88j922/nonopioid_drugs?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005356/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Medical Devices,Analgesics

KEYWORD:

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/18/2018 03:57 AM/DISC: 09/18/2018 03:57 AM

http://www.businesswire.com/news/home/20180918005356/en

AP RADIO
Update hourly